Drug Trial Radar · NCT00231764
MMF, Daclizumab and Corticosteroids as Mainstay Immunosuppression in Renal Transplant Patients
Last checked: Nov 20, 2026Latest source record: Apr 24, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,760
Actual
Start
Nov 2002
Primary completion
May 2006
Study completion Feb 2008
Sponsor
- Lead sponsor
- Ekberg, Henrik, M.D.Individual
- Sponsor type
- Individual
- Collaborators
- Prof. Philip Halloran, Edmonton, Canada (sponsor); Prof. Yves Vanrenterghem, Leuven, Belgium (Steering Committee Member); Prof. Pierre Daloze, Montréal, Canada (Steering Committee Member); Prof. Thomas C. Pearson, Atlanta, USA (Steering Committee Member); Prof. Ulrich Frei, Berlin, Germany (Steering Committee Member); Prof. Flavio Vincenti, San Francisco, USA (Ass. Steering Committee Member); Prof. Josep Grinyo, Barcelona, Spain (Ass. Steering Committee Member); Hoffmann-La Roche
- First posted
- Oct 4, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine the renal function, as expressed by the glomerular filtration rate at 12 months, in renal transplant recipients receiving mycophenolate mofetil, daclizumab, and corticosteroids as mainstay immunosuppression in combination with low-dose cyclosporine, tacrolimus, or sirolimus, and compare it to that of renal transplant recipients receiving standard immunosuppression with mycophenolate mofetil, normal dose cyclosporine and corticosteroids.
Conditions
- Kidney Transplantation
Interventions
daclizumabDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- GFR calculated from the serum creatinine with the Cockcroft-Gault formula at 12 months posttransplantation
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.